Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug taldefgrobep alfa enters Mid-Stage trial

NCT ID NCT07281495

Disease control Sponsor: Biohaven Therapeutics Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called taldefgrobep alfa (BHV-2000) to help adults with overweight or obesity lose weight. About 150 participants will receive either the drug or a placebo as a weekly or monthly injection for 24 weeks. The main goal is to see how much body weight changes, along with effects on fat and muscle mass.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
taldefgrobep alfa (BHV-2000)
What this could lead to
If successful, this could lead to a new weekly or monthly injection to help people with overweight or obesity lose weight and reduce body fat.
What could go wrong
This is an early Phase 2b trial with only 150 people, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. a. BMI \> 30 kg/m2 and BMI \< 42 kg/m2, OR b. BMI ≥ 27 kg/m2 and BMI \<30 kg/m2 with at least one weight-related co-morbidity 2. History of at least one self-reported unsuccessful dietary effort to lose body weight. 3. Stable body weight and stable physical activity within 3 months prior to screening per participant self-report. 4. All participants must adhere to protocol contraception requirements Key Exclusion Criteria: 1. History of diabetes, including individuals with a HbA1c of ≥ 6.5% at Screening 2. Non-ambulatory participants, defined as unable to take at least 10 steps independently. 3. Females currently pregnant or breastfeeding, or who intend to become pregnant or to breastfeed. 4. Participation in another investigational clinical trial while participating in this clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

Contacts and locations

Locations

  • Site-001

    Chula Vista, California, 91911, United States

  • Site-002

    Fargo, North Dakota, 58104, United States

  • Site-003

    Springfield, Missouri, 65807, United States

  • Site-004

    Arlington, Virginia, 22205, United States

  • Site-005

    Austin, Texas, 78745, United States

  • Site-006

    City of Saint Peters, Missouri, 63303, United States

  • Site-007

    Chicago, Illinois, 60625, United States

  • Site-008

    Palm Springs, Florida, 33461, United States

  • Site-009

    Metairie, Louisiana, 70006, United States

  • Site-010

    Baton Rouge, Louisiana, 70808, United States

  • Site-011

    Sacramento, California, 95821, United States

  • Site-012

    McKinney, Texas, 75069, United States

  • Site-013

    San Antonio, Texas, 78229, United States

  • Site-014

    Montclair, California, 97163, United States

  • Site-015

    St. Petersburg, Florida, 33704, United States

  • Site-016

    Indianapolis, Indiana, 46254, United States

  • Site-017

    North Charleston, South Carolina, 29405, United States

  • Site-018

    Tustin, California, 92780, United States

  • Site-019

    Monroe, North Carolina, 28112, United States

  • Site-020

    Orlando, Florida, 32804, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.